Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.
GlobalData on MSN18d
Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment
Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
The New York Times19d
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. By Brendan Borrell When Stephane Castel first ...
Benzinga.com18d
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Variant Bio to receive $50 million upfront and R&D funding in Novo Nordisk deal to identify metabolic disease targets. The companies originally partnered in September 2023 in an agreement that ...
businessday16d
Drug company shares revenue with research participants
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop ...
pharmaphorum3y
Gritstone bio trumpets first data for 'multivariant' COVID jab
A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated ... with the new Omicron variant. The results of the ...
Nylon's Sustainable Transformation: Bio-Based and Recycled Fibers Take Center Stage in Performance Apparel
The "Markets for Nylon in Performance Apparel: A Future Based on Bio-Based and Recycled Materials?" report from Textiles Intelligence Ltd. has been added to ResearchAndMarkets.com's offering. The ...